GlassScriptPhysician profile
Peyton Marie Holowsko
NPI 1528872637
$603.64
in general payments reported to CMS, 2019-2025
21 companies · $604 in 2025
The $604 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $89.89 | 2025 | |
| Novo Nordisk INC | $42.68 | 2025 | Wegovy |
| Inspire Medical Systems, INC. | $42.20 | 2025 | Inspire |
| Lundbeck LLC | $40.39 | 2025 | Rexulti |
| Csl Behring | $39.17 | 2025 | Andembry |
| Teva Pharmaceuticals USA, INC. | $35.54 | 2025 | Austedo Xr |
| Medtronic, INC. | $30.68 | 2025 | Minimed 780g |
| Phathom Pharmaceuticals, INC. | $23.71 | 2025 | Voquezna |
| Ibsa Pharma INC. | $23.54 | 2025 | Licart, Flector, Tirosint |
| Neurocrine Biosciences, INC. | $22.66 | 2025 | |
| Esperion Therapeutics, INC. | $21.83 | 2025 | Nexletol |
| Exact Sciences Corporation | $21.62 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.48 | 2025 | Jardiance |
| Lilly USA, LLC | $21.17 | 2025 | Jardiance |
| Medicomp INC | $20.12 | 2025 | Telepatch Cardiac Monitor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $19.22 | 2025 | Unithroid |
| Janssen Pharmaceuticals, INC | $19.02 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $18.34 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.59 | 2025 | Caplyta |
| Pfizer INC. | $16.57 | 2025 | |
| Glaxosmithkline, LLC. | $16.22 | 2025 | Arexvy, Bexsero, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyton Holowsko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.